GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Clearpoint Neuro CLPT · USD

Health Care · US listing · 🇺🇸 United States

Compare

6.91

-5.47%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Clearpoint Neuro — daily CLPT Delayed
Market value
$205.6m
Last close × shares
Volume
1.1m
Shares, 20 Nov 2026

About Clearpoint Neuro

From its filings with the US Securities and Exchange Commission

SEC filings

Clearpoint Neuro is based in Solana Beach, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CLPT. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $37.0m and a net loss of $25.5m. At that date it held total assets of $97.7m and shareholders' equity of $28.0m.

In its own words

We are a commercial-stage medical device company, incorporated in 1998 as a Delaware corporation, that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. From our inception in 1998, we have deployed significant resources to fund our efforts to develop the foundational capabilities for enabling magnetic resonance imaging (“MRI”) guided interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies we develop. In 2021, our efforts expanded beyond the MRI suite to encompass development and commercialization of neurosurgical device products for the operating room setting, as well as consulting services for pharmaceutical companies.

In 2025, through our acquisition of IRRAS Holdings, Inc. (“IRRAS”), we expanded our portfolio into neurocritical care. IRRAS is a commercial-stage medical technology company focused on treatments for intracerebral hemorrhage, intraventricular hemorrhage, and other conditions requiring intracranial fluid management.

The IRRAS products complement our existing neurosurgical technologies and broaden our reach into acute care settings, enabling us to offer an expanded set of solutions spanning functional neurosurgery, neurocritical care, and intracranial drug delivery.

Quoted from its 10-K, filed 17 Mar 2026. Read the filing on SEC.gov ↗

More about Clearpoint Neuro →

How it makes its money

Revenue, year to 31 Dec 2025

  • Product revenue $23.9m · 64.5%
  • Service and other revenue $13.1m · 35.5%
  • Capital Equipment and Software-Related Service $2.1m · 5.7%

Latest on Clearpoint Neuro

Our reporting

Next results

3 Mar 2027

Due on 3 Mar 2027. Analysts expect earnings of -0.23 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Clearpoint Neuro's ticker?

Clearpoint Neuro trades as CLPT on its US listing, under ISIN US18507C1036.

What was Clearpoint Neuro's last closing price?

6.91 on 20 Nov 2026. The figure is in USD and is never converted.

When does Clearpoint Neuro next report results?

Results are expected on 3 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.